Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvon Protection Regulatory News (AVON)

Share Price Information for Avon Protection (AVON)

Share Price is delayed by 15 minutes
Get Live Data
1,652.00    -2.00 (-0.12%)
Bid:
1,650.00
Ask:
1,654.00
Spread: 4.00 (0.242%)
Market Cap: £486.54m
AVON Live PriceLast checked at - London Stock Exchange

Intraday Avon Protection Share Chart

Trading Update

13 Aug 2021 07:00

RNS Number : 5232I
Avon Protection PLC
13 August 2021
 

13 August 2021

Avon Protection plc

Trading Update

 

Avon Protection plc ("Avon") today provides the following trading update for its current financial year ending 30 September 2021 ("FY21").

 

Trading update

 

Avon has continued to see good commercial progress in the second half of FY21, with order intake in the ten months to 31 July 2021 of $221m. This represents order growth, excluding Team Wendy, of 13% over the equivalent period last year, giving a strong order book of $146m (including Team Wendy), up 21% year-on-year. This progress has been driven by good results from the Team Wendy, First Responder and Military Respiratory lines of business.

 

Notwithstanding the positive demand backdrop, the impact of delays in the receipt of orders, supply chain disruption and a tight U.S. labour market has increased significantly through the second half of the financial year. Whilst this COVID-19 related disruption is expected to be temporary in nature, the impact has resulted in a reduction in our revenue guidance for FY21 to between $245m - $260m, due to:

 

· Delayed receipt of c.$16m of expected orders under existing contracts, including a significant M50 order, as a result of procurement bottlenecks;

 

· Extended lead times for predominantly electronic and textile components delaying the shipment of c.$6m of deliveries under existing orders; and

 

· Remaining uncertainties as to the timing of receipt of other orders that we expect to receive and ship before the end of the financial year.

 

The result of the lower revenue expectations, combined with an adverse mix effect and an overhead base that is fixed in the short term, means that adjusted EBITDA margin guidance is expected to reduce to between 17% - 18% for FY21, before recovering thereafter.

 

The Board is confident that the delayed orders will be received over the coming months, but expects supply chain disruption and a tight U.S. labour market to persist into next year. As a result, the Board believes it is prudent to take this into account and reduce FY22 revenue expectations to $320m - $340m, whilst maintaining current guidance for FY23.

 

The delays to product shipments have also resulted in a build-up of inventory and delayed receipts from customers which is likely to persist through the year end, with FY21 cash conversion now expected to be c.50%, based on the above revenue assumptions. Longer term cash flow dynamics continue to be strong, and the inventory position is expected to largely unwind through FY22.

 

Contract update

 

Considerable further progress has been made in respect of the delayed product approvals in the Military Ballistic business, in line with the Board's previous guidance. First Article Testing for the DLA ESAPI contract is well advanced, with initial shipments expected in the first half of FY22. Sample plates for the VTP ESAPI contract are on track to be delivered in September for testing, with initial shipments expected in the second half of FY22.

 

Avon has received a further $9m delivery order under the sole source first generation IHPS helmet contract, in addition to the $19m order already received in March. The procurement process to put in place a revised, multi-source next generation IHPS contract is well advanced and is expected to conclude before the end of September.

 

Commenting, Paul McDonald, Chief Executive Officer, said:

 

"We have made considerable commercial progress over the last 18 months in building a broad portfolio of significant, multi-year contracts across the business, with the underlying demand momentum continuing, so the short-term disruption that we are seeing is unwelcome. These issues will be resolved over the coming months, but as they are affecting both our customers and suppliers simultaneously the situation has significantly limited our operating agility in the short term.

 

We remain as confident as ever about the medium-term prospects of Avon Protection, underpinned by a record order book, a growing and visible contract pipeline and world leading businesses and technologies. We will carry significant momentum into next year, which will also benefit from a strong ramp-up in the Ballistics business, and remain well set for growth in FY22 and beyond."

 

 

For further enquiries, please contact:

 

Avon Protection plc

 

Paul McDonald, Chief Executive Officer

01225 896 848

Nick Keveth, Chief Financial Officer

 

 

 

 

 

MHP Communications

 

Andrew Jaques

0203 128 8570

Charlie Barker

avonprotection@mhpc.com

Pete Lambie

Ailsa Prestige

 

 

Legal Entity Identifier: 213800JM1AN62REBWA71

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of those Regulations.

Note to editors: 

Avon Protection plc is listed on the London Stock Exchange (LSE: AVON) and is a constituent of the FTSE 250 Index.

Avon Protection is an innovative technology group, which designs and produces life critical personal protection systems to maximise the performance and capabilities of its customers, with leading positions in the respiratory and ballistic protection markets for the world's militaries and first responders.

For further information, please visit our website www.avon-protection-plc.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFSESEEFSEDA
Date   Source Headline
13th May 20267:00 amRNSInterim Results
8th May 20267:00 amRNSHolding(s) in Company
6th May 20262:03 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSHolding(s) in Company
14th Apr 20267:00 amRNSNotice of Results and Investor Presentation
8th Apr 202612:15 pmRNSHolding(s) in Company
8th Apr 202611:47 amRNSDirector/PDMR Shareholding
27th Mar 20261:23 pmRNSDirector/PDMR Shareholding
6th Mar 20261:23 pmRNSDirectors'/PDMR Shareholdings
6th Mar 20267:00 amRNSNew Filter Order
3rd Mar 20262:34 pmRNSHolding(s) in Company
13th Feb 202611:01 amRNSDirector/PDMR Shareholding
6th Feb 20262:52 pmRNSDirectors'/PDMR Shareholdings
6th Feb 20262:41 pmRNSFinal Dividend Currency Exchange Rate
4th Feb 20264:18 pmRNSHolding(s) in Company
2nd Feb 202610:10 amRNSResult of AGM
30th Jan 20267:00 amRNSAGM & Q1 Trading Update
20th Jan 20263:19 pmRNSDirector/PDMR Shareholding
6th Jan 20261:46 pmRNSDirectors'/PDMR Shareholdings
23rd Dec 20259:21 amRNSDirector/PDMR Shareholding
23rd Dec 20259:21 amRNSDirector/PDMR Shareholding
16th Dec 20258:45 amRNSHolding(s) in Company
11th Dec 20253:51 pmRNSHolding(s) in Company
11th Dec 20257:00 amRNSEuropean FM50 Order
9th Dec 202511:58 amRNSDirectors'/PDMR Shareholding
8th Dec 20251:32 pmRNSDirectors'/PDMR Shareholdings
5th Dec 20259:00 amRNSNotice of Annual Report & Accounts and AGM 2026
1st Dec 20256:01 pmRNSDirector Declaration
25th Nov 20253:55 pmRNSHolding(s) in Company
21st Nov 20259:50 amRNSNotification of LTIP & DSBP Awards
12th Nov 20257:00 amRNSPreliminary Results
7th Nov 20259:23 amRNSDirectors'/PDMR Shareholdings
16th Oct 20257:00 amRNSNotice of Results & Investor Presentation via IMC
8th Oct 202510:06 amRNSDirectors'/PDMR Shareholding
15th Sep 20252:51 pmRNSHolding(s) in Company
11th Sep 20254:10 pmRNSHolding(s) in Company
8th Sep 20251:14 pmRNSDirectors'/PDMR Shareholding
13th Aug 20254:59 pmRNSInterim Dividend Currency Exchange Rate
11th Aug 20254:47 pmRNSHolding(s) in Company
7th Aug 20253:10 pmRNSDirectors'/PDMR Shareholdings
17th Jul 20257:00 amRNSDirectors'/PDMR Shareholdings
23rd Jun 20257:00 amRNSUK MoD respirator order for Ukraine
10th Jun 20257:00 amRNSHolding(s) in Company
9th Jun 20259:30 amRNSDirectors'/PDMR Shareholdings
5th Jun 20253:31 pmRNSUS Department of Defense Order
3rd Jun 20256:00 pmRNSRenewi
29th May 202510:00 amRNSHolding(s) in Company
21st May 20257:00 amRNSInterim Results
20th May 20254:00 pmRNSNotification of change in particulars of director
16th May 20253:00 pmRNSNotification of change in particulars of director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.